Hjem › Akut myelogen leukemi › Michigan › Detroit
Kliniske studier for Akut myelogen leukemi i Detroit, MI
14 studier for Akut myelogen leukemi søker deltakere på steder i og rundt Detroit (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekruttererFase 2
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RekruttererFase 3
- Henry Ford Health System, Detroit
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- Henry Ford Hospital, Detroit
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- Wayne State University/Karmanos Cancer Institute, Detroit
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekruttererFase 1/2
- Children's Hospital of Michigan, Detroit
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RekruttererFase 3
- Children's Hospital of Michigan, Detroit
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RekruttererFase 3
- Wayne State University School of Medicine, Detroit
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RekruttererFase 1
- Karmanos Cancer Institute, Detroit
- Henry Ford Cancer Institute, Detroit
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
RekruttererFase 3
- Henry Ford Cancer Institute, Detroit
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekruttererObservasjonsstudie
- Children's Hospital of Michigan, Detroit
- Henry Ford Health System, Detroit
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RekruttererFase 2
- Karmanos Cancer Institute, Detroit
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RekruttererFase 1
- Karmanos Cancer Institute, Detroit
HPC Offered for PRESERVE Expansion
RekruttererObservasjonsstudie
- Henry Ford Health, Detroit
Akut myelogen leukemi-studier i andre byer
- Houston, TX85 studier
- New York City, NY51 studier
- Boston, MA44 studier
- Seattle, WA41 studier
- Baldwin Park, CA40 studier
- Columbus, OH35 studier
- Philadelphia, PA34 studier
- Durham, NC33 studier
- Atlanta, GA31 studier
- Tampa, FL29 studier
- Chicago, IL26 studier
- Portland, OR25 studier
Andre studier i Detroit
- Ikke-småcellet lungekreft44 studier
- Brystkreft33 studier
- Kreft (alle typer)29 studier
- Kolorektal kreft26 studier
- Eggstokkreft26 studier
- Metastatisk kreft24 studier
- Prostatakreft22 studier
- Endometriekreft21 studier
- Lungekreft20 studier
- Multipelt myelom19 studier
- Mavekreft16 studier
- Plateepitelcancer i hode og hals15 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.